Wedbush Maintained miRagen Therapeutics Inc (MGEN) As a Buy; They Now Have a Target Of $19.0

March 14, 2018 - By Nellie Frank

 Wedbush Maintained miRagen Therapeutics Inc (MGEN) As a Buy; They Now Have a Target Of $19.0

miRagen Therapeutics Inc (MGEN) Rating Reaffirmed

In a note revealed to clients and investors this morning, Wedbush kept their Buy rating on miRagen Therapeutics Inc (MGEN) shares. The TP gives a possible upside of 168.74 % from firm’s last stock close price.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Coverage

Among 7 analysts covering Miragen Therapeutics (MGEN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Miragen Therapeutics has $19.0 highest and $13.0 lowest target. $16.40’s average target is 131.97% above currents $7.07 stock price. Miragen Therapeutics had 11 analyst reports since February 21, 2017 according to SRatingsIntel. Oppenheimer initiated Miragen Therapeutics, Inc. (NASDAQ:MGEN) rating on Thursday, January 11. Oppenheimer has “Buy” rating and $13.0 target. The rating was initiated by Wedbush with “Outperform” on Tuesday, February 21. The firm has “Buy” rating given on Monday, August 14 by Chardan Capital Markets. The firm has “Buy” rating given on Friday, February 2 by FBR Capital. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) earned “Buy” rating by Wedbush on Friday, December 1. The firm has “Buy” rating given on Friday, August 18 by Wedbush. The rating was maintained by Wedbush on Monday, October 16 with “Buy”.

The stock increased 0.71% or $0.05 during the last trading session, reaching $7.07. About 223,355 shares traded. Miragen Therapeutics, Inc. (MGEN) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $207.16 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The companyÂ’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More notable recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: which released: “miRagen Therapeutics to Present at the Cantor Fitzgerald Global Healthcare …” on September 01, 2017, also with their article: “Miragen Therapeutics May Provide Long-Term Alpha Within The RNA Space” published on February 01, 2018, published: “miRagen Therapeutics to Participate in Upcoming Investor Conferences” on March 05, 2018. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) were released by: and their article: “miRagen Therapeutics, Inc. Prices Public Offering of Common Stock” published on February 08, 2018 as well as‘s news article titled: “miRagen Therapeutics (MGEN) Announces Proposed 7M Share Common Offering” with publication date: February 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: